BACKGROUND: Some patients diagnosed with early-stage lung cancer and treated according to standard care survive for only a short period of time, while others survive for years for reasons that are not well understood. Associations between markers of inflammation and survival from lung cancer have been observed. MATERIALS AND METHODS: Here, we investigate whether circulating levels of 77 inflammatory markers are associated with long versus short survival in stage I and II lung cancer. Patients who had survived either <79 weeks (~1.5 years) (short survivors, SS) or >156 weeks (3 years) (long survivors, LS) were selected from a retrospective population-based study. Logistic regression was used to calculate adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs). The false discovery rate was calculated to adjust for multiple testing. RESULTS: A total of 157 LS and 84 SS were included in this analysis. Thirteen markers had adjusted OR on the order of 2- to 5-fold when comparing the upper and lower quartiles with regard to the odds of short survival versus long. Chemokine CCL15 [chemokine (C-C motif) ligand 15] was the most significant marker associated with increased odds of short survival (ORs = 4.93; 95% CI 1.90-12.8; q-value: 0.042). Smoking and chronic obstructive pulmonary disease were not associated with marker levels. CONCLUSIONS: Our results provide some evidence that deregulation of inflammatory responses may play a role in the survival of early-stage lung cancer. These findings will require confirmation in future studies.
BACKGROUND: Some patients diagnosed with early-stage lung cancer and treated according to standard care survive for only a short period of time, while others survive for years for reasons that are not well understood. Associations between markers of inflammation and survival from lung cancer have been observed. MATERIALS AND METHODS: Here, we investigate whether circulating levels of 77 inflammatory markers are associated with long versus short survival in stage I and II lung cancer. Patients who had survived either <79 weeks (~1.5 years) (short survivors, SS) or >156 weeks (3 years) (long survivors, LS) were selected from a retrospective population-based study. Logistic regression was used to calculate adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs). The false discovery rate was calculated to adjust for multiple testing. RESULTS: A total of 157 LS and 84 SS were included in this analysis. Thirteen markers had adjusted OR on the order of 2- to 5-fold when comparing the upper and lower quartiles with regard to the odds of short survival versus long. Chemokine CCL15 [chemokine (C-C motif) ligand 15] was the most significant marker associated with increased odds of short survival (ORs = 4.93; 95% CI 1.90-12.8; q-value: 0.042). Smoking and chronic obstructive pulmonary disease were not associated with marker levels. CONCLUSIONS: Our results provide some evidence that deregulation of inflammatory responses may play a role in the survival of early-stage lung cancer. These findings will require confirmation in future studies.
Authors: Peyman Sardari Nia; Joost Weyler; Cecile Colpaert; Peter Vermeulen; Eric Van Marck; Paul Van Schil Journal: Lung Cancer Date: 2005-03 Impact factor: 5.705
Authors: A Pardigol; U Forssmann; H D Zucht; P Loetscher; P Schulz-Knappe; M Baggiolini; W G Forssmann; H J Mägert Journal: Proc Natl Acad Sci U S A Date: 1998-05-26 Impact factor: 11.205
Authors: Jesang Ko; In Sik Kim; Sung Wuk Jang; Young Han Lee; Soon Young Shin; Do Sik Min; Doe Sun Na Journal: FEBS Lett Date: 2002-03-27 Impact factor: 4.124
Authors: P Joubert; S Lajoie-Kadoch; V Wellemans; S Létuvé; M K Tulic; A J Halayko; Q Hamid Journal: Clin Exp Allergy Date: 2011-11-09 Impact factor: 5.018
Authors: Heikki Joensuu; Anu Anttonen; Minna Eriksson; Riitta Mäkitaro; Henrik Alfthan; Vuokko Kinnula; Sirpa Leppä Journal: Cancer Res Date: 2002-09-15 Impact factor: 12.701
Authors: Eric S White; Kevin R Flaherty; Shannon Carskadon; Ashley Brant; Mark D Iannettoni; John Yee; Mark B Orringer; Douglas A Arenberg Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: Troy J Kemp; Felipe A Castro; Yu-Tang Gao; Allan Hildesheim; Leticia Nogueira; Bing-Sheng Wang; Lu Sun; Gloriana Shelton; Ruth M Pfeiffer; Ann W Hsing; Ligia A Pinto; Jill Koshiol Journal: Cytokine Date: 2015-03-02 Impact factor: 3.861